Herpes simplex virus keratitis

Summary

Herpes simplex virus keratitis (MONDO:0015288) is a disease and 4 clinical trials. Top therapeutic interventions include acyclovir and ganciclovir. A subtype of herpes simplex infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 4

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	herpes simplex virus keratitis
Mondo ID	MONDO:0015288
EFO	EFO:0007308
Orphanet	137586
DOID	DOID:0080158
NCIT	C34743
SNOMED CT	9389005
UMLS	C0019357
MedGen	5534
GARD	0025063
Is cancer (heuristic)	no

Also known as: dendritic keratitis · herpetic keratitis · HSV keratitis · Simplexvirus caused keratitis · Simplexvirus keratitis

Disease family

This is a subtype of herpes simplex infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › viral infectious disease › primary viral infectious disease › Herpesviridae infectious disease › herpes simplex infectious disease › herpes simplex virus keratitis

Related subtypes (9): herpetic whitlow, herpes simplex dermatitis, genital herpes, herpes simplex virus gingivostomatitis, herpes simplex encephalitis, congenital herpes simplex virus infection, herpes labialis, herpes simplex type 1 infectious disease, herpes simplex type 2 infectious disease

Subtypes (2): stromal keratitis, endotheliitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 1 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Prednisolone Phosphoric Acid	Phase 3 (in late-stage trials)

Clinical trials & evidence

Clinical trials

Clinical trials: 4.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	3
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03626376	PHASE4	WITHDRAWN	Topical Corticosteroid Use in Addition to Oral Antivirals for Prevention of Recurrence of Herpes Simplex Virus (HSV) Keratitis
NCT04384094	Not specified	UNKNOWN	Defining the Operating Parameters for a Rebound-esthesiometer
NCT04420429	Not specified	COMPLETED	The Effect Of Preoperative Parameters On Success After DMEK Surgery
NCT06757907	Not specified	COMPLETED	Topical Ganciclovir Versus Systemic Aciclovir in the Treatment of Herpetic Keratitis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ACYCLOVIR	4	1
GANCICLOVIR	4	1